Table 2.
Treatment Effect of Ivacaftor with Respect to the Change from Baseline through Week 48 in the Percent of Predicted FEV1, According to Subgroups.*
Subgroup | Treatment Effect | P Value |
---|---|---|
Baseline % of predicted FEV1 | ||
<70% | 10.6 | <0.001 |
≥70% | 10.3 | <0.001 |
Geographic region | ||
North America | 9.0 | <0.001 |
Europe | 9.9 | <0.001 |
Australia | 11.9 | 0.008 |
Sex | ||
Male | 11.0 | <0.001 |
Female | 11.6 | <0.001 |
Age | ||
<18 yr | 11.4 | 0.005 |
≥18 yr | 9.9 | <0.001 |
The treatment effect represents the difference between the ivacaftor group and the placebo group with respect to the absolute change from baseline through week 48 in the percent of predicted FEV1.